Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Theravance Biopharma (TBPH) over the last 10 years, with Q3 2025 value amounting to $573000.0.

  • Theravance Biopharma's Interest Expenses fell 904.76% to $573000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 15.84%. This contributed to the annual value of $2.5 million for FY2024, which is 834.04% up from last year.
  • Per Theravance Biopharma's latest filing, its Interest Expenses stood at $573000.0 for Q3 2025, which was down 904.76% from $663000.0 recorded in Q2 2025.
  • Theravance Biopharma's 5-year Interest Expenses high stood at $11.9 million for Q1 2021, and its period low was $550000.0 during Q4 2022.
  • For the 5-year period, Theravance Biopharma's Interest Expenses averaged around $2.2 million, with its median value being $643000.0 (2024).
  • As far as peak fluctuations go, Theravance Biopharma's Interest Expenses soared by 10877.33% in 2021, and later plummeted by 8200.12% in 2022.
  • Theravance Biopharma's Interest Expenses (Quarter) stood at $2.1 million in 2021, then plummeted by 74.26% to $550000.0 in 2022, then increased by 13.27% to $623000.0 in 2023, then rose by 3.21% to $643000.0 in 2024, then decreased by 10.89% to $573000.0 in 2025.
  • Its Interest Expenses stands at $573000.0 for Q3 2025, versus $663000.0 for Q2 2025 and $643000.0 for Q1 2025.